滤泡性淋巴瘤是一种常见的非霍奇金淋巴瘤，可以始于全身多种组织。虽然大多数患者可能能够在这种疾病中生存多年，但治愈仍然非常困难。我们试图使用大型国家数据库来研究早期疾病中滤泡性淋巴瘤原发部位对患者结果的影响。基线从 NCI 监测、流行病学和最终结果 (SEER) 数据库中确定并提取了 2000 年至 2015 年诊断为滤泡性淋巴瘤的患者的人口统计和疾病数据。原发疾病部位分为两组之一：淋巴结疾病（淋巴结和脾脏）和结外疾病（其他所有疾病）。使用汇总统计、Kaplan-Meier 方法和 Cox 比例风险模型进行单变量和多变量分析。最终分析共纳入 13,400 名患者，大多数为非西班牙裔白人 (81%)，分期I (63%) 和结节 FL (79%)。淋巴结疾病的中位总生存期为 15.1 年 [95% CI (14.6-15.6)]，而结外疾病的中位总生存期为 15.8 年 [95% CI (14.9-16.3)]。结外疾病患者的总生存率稍好一些 [HR = 0.89，95% CI (0.84-0.96)； p 值 = 0.00012]。在控制年龄和种族后，这一发现仍然一致[HR = 0.84，95% CI (0.79-0.90)； p 值 <0.0001]。早期滤泡性淋巴瘤的主要受累部位可能会对患者的治疗结果产生影响，需要进一步调查。版权所有 © 2024 Elsevier Inc. 保留所有权利。

Follicular lymphoma is a common non-Hodgkin lymphoma that can start in a diverse array of tissues throughout the body. While the majority of patients may be able to live many years with this disease, cure remains very difficult to achieve.We sought to investigate the impact of follicular lymphoma primary disease site in early-stage disease on patient outcomes using a large national database.Baseline demographic and disease data for patients diagnosed with follicular lymphoma from 2000-2015 was identified and extracted from the NCI Surveillance, Epidemiology, and End Results (SEER) database. Primary disease sites were grouped into one of two cohorts: nodal disease (lymph nodes and spleen) and extranodal disease (everything else). Analysis was performed using summary statistics, Kaplan-Meier method, and Cox-proportional hazards models for univariate and multivariate analysis.A total of 13,400 patients were included in the final analysis and the majority were non-Hispanic white (81%), with stage I (63%), and nodal FL (79%). Median overall survival for nodal disease was 15.1 years [95% CI (14.6-15.6)] while median overall survival for extranodal disease was 15.8 years [95% CI (14.9-16.3)]. Overall survival was slightly better for patients with extranodal disease [HR = 0.89, 95% CI (0.84-0.96); p-value = 0.00012]. This finding remained consistent after controlling for age and race [HR = 0.84, 95% CI (0.79-0.90); p-value <0.0001].The primary site of involvement by early-stage follicular lymphoma may have an impact on patient outcomes and warrants further investigation.Copyright © 2024 Elsevier Inc. All rights reserved.